NCT04614038 is a clinical trial of DETEC® pH in Diabetic Foot Ulcer, sponsored by Progenitec Inc..

Who is sponsoring NCT04614038?

NCT04614038 is sponsored by Progenitec Inc..

What drugs are being tested in NCT04614038?

Interventions in NCT04614038: DETEC® pH.

What condition does NCT04614038 study?

NCT04614038 studies Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer, Wound, Non-Healed.

Is NCT04614038 still recruiting?

NCT04614038 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT04614038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DETEC® pH Point of Care Wound Diagnostic Test

Status unknown Last updated 18 November 2023

What this trial tests

trial testing DETEC® pH in Diabetic Foot Ulcer in 450 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Progenitec Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	1 January 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	2 locations across United States

Drugs / interventions tested

DETEC® pH

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
Venous Leg Ulcer — all drugs for Venous Leg Ulcer →
Pressure Ulcer — all drugs for Pressure Ulcer →
Wound, Non-Healed — all drugs for Wound, Non-Healed →

Sponsor

Progenitec Inc.

Who can join

21 and older, any sex, with Diabetic Foot Ulcer or Venous Leg Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the relationship between wound alkalinity and the non-healing status of chronic ulcer wounds. It is hypothesized that wounds with an alkaline environment as indicated by DETEC pH will have a high chance of not healing over 12 weeks of wound care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

What's New in Wound Healing: Treatment Advances and Microbial Insights.
Beraja GE, Gruzmark F, Pastar I, Lev-Tov H. · · 2025 · cited 2× · PMID 40498297 · DOI 10.1007/s40257-025-00953-9

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Other Progenitec Inc. trials

Trials by the same sponsor.

NCT04614870 — DETEC® Esterase for Screening Wound Infection at Point of Care · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04614038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Progenitec Inc.
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04614038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing